title: Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
abstract: Highly active antiretroviral therapy has dramatically improved the quality of life and life expectancy of patients with human immunodeficiency virus. However, the prolonged use of HAART leads to severe metabolic adverse events. Both HIV infection and HAART can cause changes in lipid and glucose metabolism as well as elevation of blood pressure, promoting the development of atherosclerosis. Cardiovascular diseases have become a major cause of mortality among HIV-infected subjects who respond well to antiretroviral therapy. Nevertheless, a proper lifestyle and pharmacologic intervention can improve cardiovascular risk factors in the HIV-treated population and significantly reduce healthcare investments in the treatment of future cardiovascular complications in this population. In this review we summarize the current knowledge of CVD prevention and treatment in HIV patients.
authors.affiliation: Clinical Immunology, Allergy and Neve-Or AIDS Center, Kaplan Medical Center, Rehovot, Israel.
authors.forename: Eli
authors.initials: E
authors.lastname: Magen
authors.forename: Daniel
authors.initials: D
authors.lastname: Elbirt
authors.forename: Zev
authors.initials: Z
authors.lastname: Sthoeger
mesh_terms: D044966:Anti-Retroviral Agents / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000209:etiology / Q000517:prevention & control; D018149:Glucose Intolerance / Q000209:etiology / Q000517:prevention & control; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008019:Life Style; D012307:Risk Factors
chemical_list: D044966:Anti-Retroviral Agents; D000960:Hypolipidemic Agents